



441 Charmany Drive
Madison, WI 53719

May 27, 2016

To: submissions@nccn.org

Re: Submission Request – Colon Cancer

Submitted by:

Name: Mark Koppel, MD, Vice President, Medical Affairs

Company: Exact Sciences Inc.

Address: 441 Charmany Dr, Madison, WI 53719

Phone: (608) 284-5700

E-mail: mkoppel@exactsciences.com

Date of request: 5/25/2016

NCCN Guidelines Panel: Colon/Rectal/Anal Cancers

On behalf of Exact Sciences, I respectfully request the NCCN Colon/Rectal/Anal Cancers Panel to review the enclosed data for inclusion of **Cologuard™** as a recommended option for colorectal cancer screening.

Specific Changes: Recommend Cologuard as an option for colorectal cancer screening in average risk patients of either sex aged 50 years or older with a testing interval of 3 (three) years.

(Proposed bullet: The panel recommends that Cologuard be utilized as a colorectal cancer screening test for patients of either sex aged 50 years or older at average risk of colorectal cancer. The panel further recommends that Cologuard be provided as an option for colorectal cancer screening with an interval of 3 (three) years.)

FDA Clearance: Cologuard received FDA PMA clearance on August 11, 2014 (P130017).

Rationale: Inclusion of Cologuard (clinically validated in over 10,000 patients) as an option for colorectal cancer screening provides a noninvasive screening test capable of detecting more cancer and pre-cancers than other leading noninvasive tests. Furthermore, Cologuard's imbedded Patient Navigation program helps to increase compliance and the number of patients being screened for colorectal cancer.

The following articles are submitted in support of this proposed change.

Analytical validation study:

1. Lidgard, G. et al. Clinical Performance of an Automated Stool DNA Assay for Detection of Colorectal Neoplasia. *Clinical Gastroenterology and Hepatology* 2013;11:1313–1318.


Clinical validation studies:

2. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *The New England Journal of Medicine*. 2014;370:1287-1297.
3. Redwood DG, Asay ED, Blake ID, et al. Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. *Mayo Clinic Proceedings*. 2015.

Clinical utility studies:

4. Berger BM, Schroy PC, Dinh TA. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness. *Clinical Colorectal Cancer*. 2015.
5. Berger BM, Parton MA, Levin B. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing. *The American Journal of Managed Care*. 2016;22:e77-81.
6. Cyhaniuk A, Coombes ME. Longitudinal adherence to colorectal cancer screening guidelines. *The American Journal of Managed Care*. 2016;22:105-111.
7. Berger BM, Levin, B, Hilsden, RJ. Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines. *World Journal of Gastrointestinal Oncology*. 2016; 8(5): 450-458.

Sincerely,

A handwritten signature in blue ink that reads "Mark Koppel". The signature is written in a cursive, flowing style.

Mark Koppel, MD
Vice President, Medical Affairs